CAR-T细胞治疗进入癌症护理快车道

icartab

CAR T-cells merge into the fast lane of cancer care.

Abstract

Chimeric Antigen Receptors (CARs) can be introduced into T- cells redirecting them to target specific tumor antigens. CAR-modified T cells targeting CD19 have shown remarkable activity against CD19+ malignancies including B cell acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL)and non-Hodgkin lymphomas (NHL). Complete remission rates as high as 90% have been observed for patients with relapsed and refractory ALL and >50% response rates have been seen in heavily pre-treated CLL and NHL. Excitingly, some remissions have been durable without any additional therapy, a finding which correlates with in-vivo T-cell persistence and B-cell aplasia. The major treatment related toxicities include B cell aplasia, neurologic toxicities, and a potentially severe cytokine release syndrome. This review summarizes outcomes for patients treated with CD19-CAR T-cells while exploring the field's challenges and future directions. This article is protected by copyright.

  

CAR-T细胞治疗进入癌症护理快车道

摘要:

嵌合抗原受体(CARS)能够引入到T 细胞表面，能够指导它们靶向对抗特异性肿瘤抗体。靶向CD19的 CAR修饰的T细胞已经对CD19阳性肿瘤细胞包括B 淋巴细胞急性性白血病（ALL）、慢性淋巴细胞白血病（CLL）和非霍奇金淋巴瘤（NHL）显示出了显著的活性。在复发性/难治性ALL病人中能够观察到完全缓解的有效率高达90%，在严重预处理的CLL和NHL患者中观察到的完全缓解的有效率大于50%。令人激动的是，不需要其他额外的治疗，一些缓解是能够持续起作用的，这一发现与体内T细胞的持续性和B细胞发育不全有关。与治疗相关的主要毒性包括B细胞发育不全，神经系统毒性和潜在的严重的细胞因子释放综合征。这篇综述总结了使用CD19-CAR T细胞治疗病人的一些结果，同时也在探索该领域的挑战和确定未来发展方向。

出自爱康得